Compare Charles River Laboratories Intl. Inc (CRL) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 11.4× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| CRL | IEMG | |
|---|---|---|
Market Cap | $14.23B | $162.00B |
Volume | 1,176,885 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $310.77 | $86.00 |
52-Week Low | $149.93 | $64.22 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
